Joseph Senn
About Joseph Senn
Joseph Senn is the Senior Vice President and Head of Research and Development at SalioGen Therapeutics, where he has worked since 2023. He has a robust background in pharmacology and toxicology, with extensive experience in nonclinical development across several leading biotechnology companies.
Work at SalioGen Therapeutics
Joseph Senn currently serves as the Senior Vice President, Head of Research and Development at SalioGen Therapeutics. He has held this position since 2023 in Lexington, Massachusetts. In this role, he oversees the research and development initiatives of the company, contributing to the advancement of innovative therapeutic solutions.
Previous Roles in Biotechnology
Before joining SalioGen Therapeutics, Joseph Senn worked at Moderna for two years as Vice President of Nonclinical Sciences from 2020 to 2022 and previously as Head of Nonclinical Sciences from 2017 to 2020. His experience at Moderna involved overseeing the development of over 40 candidates into clinical stages. He also held various roles at Takeda Oncology, including Site Head and Therapeutic Area Lead for Drug Safety Evaluation.
Education and Expertise
Joseph Senn earned a Doctor of Philosophy (PhD) in Pharmacology from the University of Rochester School of Medicine and Dentistry, where he focused on immunology and endocrinology. He also holds a Bachelor of Science in Biology from Niagara University. His formal education and extensive training in regulatory guidance enhance his expertise in toxicology and drug development.
Professional Certifications
Joseph Senn possesses board certification as a toxicologist, reflecting his professional qualifications in the field. This certification underscores his extensive experience in writing and filing regulatory documents, including IND/CTA, IB, and NDA submissions, which are critical in the drug development process.
Broad Experience in Therapeutic Development
Joseph Senn has a diverse background in the development of multiple modalities of therapy, including small molecules, biologics, antisense, gene editing, and mRNA therapeutics. His comprehensive experience in these areas positions him as a knowledgeable leader in the biotechnology sector, particularly in advancing innovative treatment options.